Cannasouth Limited

Equities

CBD

NZCBDE0009S6

Biotechnology & Medical Research

End-of-day quote New Zealand S.E. Other stock markets 04:30:00 25/03/2024 am IST			5-day change	1st Jan Change
0.098 ^NZD	+2.08%		-.--%	-26.32%

06:33am	Cannasouth Sets Watershed Meeting for June 7	MT
15/04	Cannasouth Terminates COO	MT

Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2019

February 28, 2020 at 06:43 pm IST

Cannasouth Limited announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was NZD 410,995. Net loss was NZD 2.181 million. Basic loss per share was NZD 0.0234.

Latest news about Cannasouth Limited

Cannasouth Sets Watershed Meeting for June 7	10:03am	MT
Cannasouth Terminates COO	15/04	MT
New Zealand Shares Fall on Rate Cut Woes; Cannasouth's CEO Resigns	11/04	MT
Cannasouth CEO Resigns	11/04	MT
Cannasouth Enters Voluntary Administration, CFO Resigns	28/03	MT
Cannasouth Extends Trading Halt, Mulls Restructuring Options	28/03	MT
Cannasouth Shares Placed on Trading Halt	26/03	MT
Cannasouth Limited Reports Revenue Results for the Month of December 2023	23/01	CI
Cannasouth Issues NZ$1.1 Million Convertible Bonds	21/12	MT
Cannasouth Raises Over NZ$2 Million from Sale of Shares, Bonds	12/12	MT
Cannasouth Limited acquired Eqalis Group New Zealand Limited from Eqalis shareholders.	30/23/30	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	29/23/29	CI
Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Cannasouth Limited signed a binding term sheet to acquire Eqalis Group New Zealand Limited from Eqalis shareholders for NZD 44.4 million.	19/22/19	CI
Cannasouth Limited Reports Earnings Results for the Half Year Ended June 30, 2022	10/22/10	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	31/22/31	CI
Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01	CI
Cannasouth Limited completed the acquisition of remaining 50% stake in Cannasouth Cultivation Limited from Aaron Craig.	30/21/30	CI
Cannasouth Limited Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 June 2021	30/21/30	CI
Cannasouth Limited completed the acquisition of remaining 40% stake in Midwest Pharmaceutics NZ Limited from Greenmeadows Health Limited and Mark Balchin.	02/21/02	CI
Cannasouth Limited signed an agreement to acquire remaining 50% stake in Cannasouth Cultivation Limited from Aaron Craig.	04/21/04	CI
Cannasouth Limited agreed to acquire remaining 40% of stake in Midwest Pharmaceutics NZ Limited from Greenmeadows Health Limited and Mark Balchin for NZD 1 million.	04/21/04	CI
Cannasouth Limited Approves Election of Christine Pears as Non-Executive Independent Director	02/21/02	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	30/21/30	CI
Cannasouth Limited Announces Unaudited Earnings Results for the Year Ended December 31, 2020	25/21/25	CI

Chart Cannasouth Limited

Duration

Period

More charts

Company Profile

Cannasouth Limited is a New Zealand-based biopharmaceutical company focused on medicinal cannabis. The Company is vertically integrated, with business activities ranging from the production and supply of cannabis flower, manufacturing of cannabis-based ingredients and finished dosage products. It also offers an online clinic, and related activities, such as research and development, marketing, and sales. The Company provides a range of imported, Cannasouth-branded medicinal cannabis products. Its subsidiaries include Eqalis Pharmaceuticals Limited, Eqalis Innovation Limited, Cannasouth Bioscience Limited, and Cannasouth Cultivation Limited.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CANNASOUTH LIMITED	-26.32%	19.93M
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+37.77%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research